Cullinan Therapeutics (CGEM) Accumulated Expenses (2020 - 2026)

Cullinan Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $31.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 41.23% year-over-year to $31.9 million; the TTM figure through Mar 2026 stood at $31.9 million (up 41.23% YoY), while the FY2025 annual figure was $36.1 million, up 30.57% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $31.9 million, down from $36.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $36.1 million in Q4 2025, with the low at $2.4 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $20.7 million (2024), against an average of $18.1 million.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses sank 58.83% in 2022, then soared 766.51% in 2024.
• Cullinan Therapeutics' Accumulated Expenses stood at $14.1 million in 2022, then jumped by 71.23% to $24.2 million in 2023, then grew by 14.29% to $27.7 million in 2024, then soared by 30.57% to $36.1 million in 2025, then fell by 11.63% to $31.9 million in 2026.
• Business Quant data shows CGEM's Accumulated Expenses at $31.9 million in Q1 2026, $36.1 million in Q4 2025, and $29.8 million in Q3 2025.